~~<i id='04BCB3B227'><strike id='04BCB3B227'><tt id='04BCB3B227'><pre id='04BCB3B227'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：leisure time 2025-10-01 00:30:31 Page View：57243

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Vir antibody drug aimed at influenza A fails in clinical trial
Next article： The cancer drug shortage isn’t new — and neither are the solutions

comprehensive

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

Sanofi seeks simpler, safer CRISPR sickle cell cure

RubyWallauforSTATSanofiwilllicenseanewCRISPRenzymefromthestartupScribeTherapeuticsinabidtobethefirst

Affirmative action in medical school literally saved lives

AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

2:04ACanadairfirefightingplanesprayswaterduringafireinDervenochoria,north-westofAthens,onJuly19,2023